Cargando…
Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses
Cancer antigen 125 (CA125) is a valuable tumor marker for ovarian cancer. Gynecology Imaging Reporting and Data System (GI-RADS) is proved to be effective at identifying the adnexal masses. We investigated whether the combination of these two methods can improve the diagnostic accuracy of ovarian ca...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408110/ https://www.ncbi.nlm.nih.gov/pubmed/30762809 http://dx.doi.org/10.1097/MD.0000000000014577 |
_version_ | 1783401708645253120 |
---|---|
author | Zheng, Heng Tie, Yan Wang, Xi Yang, Yang Wei, Xiawei Zhao, Xia |
author_facet | Zheng, Heng Tie, Yan Wang, Xi Yang, Yang Wei, Xiawei Zhao, Xia |
author_sort | Zheng, Heng |
collection | PubMed |
description | Cancer antigen 125 (CA125) is a valuable tumor marker for ovarian cancer. Gynecology Imaging Reporting and Data System (GI-RADS) is proved to be effective at identifying the adnexal masses. We investigated whether the combination of these two methods can improve the diagnostic accuracy of ovarian cancer. We retrospectively analyzed preoperative data of 325 patients diagnosed with suspected adnexal mass, 196 patients with benign ovarian masses and 129 with malignant ovarian cancer (stage I: 34, II: 16, III: 61, IV: 18). CA125 was analyzed using the ARCHITECT system, GI-RADS was evaluated according to the International Ovarian Tumor Analysis consensus nomenclature and definitions. Sensitivities and specificities were also calculated for GI-RADS, CA125 and the combinations. The sensitivity, specificity and accuracy of CA125, GI-RADS were 75.97%, 79.59%, 78.15%, and 90.70%, 90.82%,90.77%, the combination data were 94.79%, 96.00%,95.53%. The AUC of combined diagnostic methods was the largest and significantly better compared with each method alone, P < .001). For stage I-II malignancy, GI-RADS as a single method was superior to CA125. Combined use of serum CA 125 and GI-RADS system improved the identification of adnexal masses at high risk of malignancy and could be used for clinical decision-making. |
format | Online Article Text |
id | pubmed-6408110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-64081102019-03-16 Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses Zheng, Heng Tie, Yan Wang, Xi Yang, Yang Wei, Xiawei Zhao, Xia Medicine (Baltimore) Research Article Cancer antigen 125 (CA125) is a valuable tumor marker for ovarian cancer. Gynecology Imaging Reporting and Data System (GI-RADS) is proved to be effective at identifying the adnexal masses. We investigated whether the combination of these two methods can improve the diagnostic accuracy of ovarian cancer. We retrospectively analyzed preoperative data of 325 patients diagnosed with suspected adnexal mass, 196 patients with benign ovarian masses and 129 with malignant ovarian cancer (stage I: 34, II: 16, III: 61, IV: 18). CA125 was analyzed using the ARCHITECT system, GI-RADS was evaluated according to the International Ovarian Tumor Analysis consensus nomenclature and definitions. Sensitivities and specificities were also calculated for GI-RADS, CA125 and the combinations. The sensitivity, specificity and accuracy of CA125, GI-RADS were 75.97%, 79.59%, 78.15%, and 90.70%, 90.82%,90.77%, the combination data were 94.79%, 96.00%,95.53%. The AUC of combined diagnostic methods was the largest and significantly better compared with each method alone, P < .001). For stage I-II malignancy, GI-RADS as a single method was superior to CA125. Combined use of serum CA 125 and GI-RADS system improved the identification of adnexal masses at high risk of malignancy and could be used for clinical decision-making. Wolters Kluwer Health 2019-02-15 /pmc/articles/PMC6408110/ /pubmed/30762809 http://dx.doi.org/10.1097/MD.0000000000014577 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Zheng, Heng Tie, Yan Wang, Xi Yang, Yang Wei, Xiawei Zhao, Xia Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses |
title | Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses |
title_full | Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses |
title_fullStr | Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses |
title_full_unstemmed | Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses |
title_short | Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses |
title_sort | assessment of the diagnostic value of using serum ca125 and gi-rads system in the evaluation of adnexal masses |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408110/ https://www.ncbi.nlm.nih.gov/pubmed/30762809 http://dx.doi.org/10.1097/MD.0000000000014577 |
work_keys_str_mv | AT zhengheng assessmentofthediagnosticvalueofusingserumca125andgiradssystemintheevaluationofadnexalmasses AT tieyan assessmentofthediagnosticvalueofusingserumca125andgiradssystemintheevaluationofadnexalmasses AT wangxi assessmentofthediagnosticvalueofusingserumca125andgiradssystemintheevaluationofadnexalmasses AT yangyang assessmentofthediagnosticvalueofusingserumca125andgiradssystemintheevaluationofadnexalmasses AT weixiawei assessmentofthediagnosticvalueofusingserumca125andgiradssystemintheevaluationofadnexalmasses AT zhaoxia assessmentofthediagnosticvalueofusingserumca125andgiradssystemintheevaluationofadnexalmasses |